CTTC — Calmare Therapeutics Share Price
Last trade - 00:00- $0.00m
- $5.59m
- $1.11m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -346.47% | ||
Financial Summary
| Year End 31st Dec | Unit | 2012 | 2013 | 2014 | 2015 | 2016 | 2017E | 2018E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.91 | 0.65 | 1.05 | 0.89 | 1.11 | n/a | n/a | -20.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Calmare Therapeutics Incorporated is a biotherapeutic company. The Company’s medical devices offer a non-pharmacological (no drugs), non-addictive (no narcotics) and non-invasive (over the skin) solution to chronic pain sufferers in an outpatient treatment setting. It supplements its medical devices with a catalog of private label neurostimulation and sensory electrodes. Its flagship medical device, the Calmare Pain Therapy Device is a non-invasive and non-addictive modality that treats chronic and neuropathic pain. Its devices are commercially sold to medical practices throughout the world. Its technology portfolio includes PMT 1, Neuroprotection and Cognitive Enhancement, Sexual Dysfunction Therapeutic, Skin Pigment Enhancer and Wound Sealant. The Company's clients include universities, corporations, and inventors.
Directors
- Peter Brennan CHM (60)
- Conrad Mir PRE (46)
- Thomas Richtarich CFO (64)
- Stephen D'Amato OTH
- Santanu Das DRC
- Rustin Howard IND (58)
- Stanley Yarbro IND (70)
- Last Annual
- December 31st, 2016
- Last Interim
- December 31st, 2016
- Incorporated
- August 12th, 1971
- Public Since
- January 1st, 1970
- No. of Employees
- 7
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 38,997,971
- Address
- 1375 Kings Highway East, FAIRFIELD, 06824
- Web
- http://calmaretherapeutics.com/
- Phone
- +1 2033686044
- Contact
- Conrad Mir
- Auditors
- Mayer Hoffman & McCann P.C.
Upcoming Events for CTTC
Similar to CTTC
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
Agape ATP
Pink Sheets on Nasdaq
FAQ
As of Today at 01:04 UTC, shares in Calmare Therapeutics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Calmare Therapeutics last closed at $0.00 and the price had moved by -99.99% over the past 365 days. In terms of relative price strength the Calmare Therapeutics share price has underperformed the S&P500 Index by -99.99% over the past year.
There is no consensus recommendation for this security.
Calmare Therapeutics does not currently pay a dividend.
Calmare Therapeutics does not currently pay a dividend.
Calmare Therapeutics does not currently pay a dividend.
To buy shares in Calmare Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Calmare Therapeutics had a market capitalisation of $0.00m.
Here are the trading details for Calmare Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CTTC
Based on an overall assessment of its quality, value and momentum Calmare Therapeutics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Calmare Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -99.09%.
As of the last closing price of $0.00, shares in Calmare Therapeutics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Calmare Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Calmare Therapeutics' management team is headed by:
- Peter Brennan - CHM
- Conrad Mir - PRE
- Thomas Richtarich - CFO
- Stephen D'Amato - OTH
- Santanu Das - DRC
- Rustin Howard - IND
- Stanley Yarbro - IND